Pricing Log in Create free account

Celcuity, Inc. (CELC) vs Denali Therapeutics Inc. (DNLI)

Celcuity, Inc. and Denali Therapeutics Inc. are both Biotechnology companies. Celcuity, Inc. and Denali Therapeutics Inc. are of similar size ($3.2B and $3.1B). Celcuity, Inc. has the higher net margin (0.00% vs −1,388.2%) and the higher return on invested capital (0.00% vs −80.0%). Across the 13 metrics below, Celcuity, Inc. leads on 9 and Denali Therapeutics Inc. on 4.

Valuation

Metric CELC DNLI Biotechnology median
P/E n/m n/m 10.26
P/S n/m 165.44 9.18
P/B n/m 4.04 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 142.89 8.98
Earnings yield (6.66%) (8.69%) (34.89%)
Free cash flow yield (5.43%) (12.01%) (24.52%)

Profitability

Metric CELC DNLI Biotechnology median
Gross margin 0.00% 98.74% 65.16%
Operating margin 0.00% (2,348.95%) 0.00%
Net margin 0.00% (1,388.24%) 0.00%
Free cash flow margin 0.00% (1,986.81%) 0.00%
Return on equity (1,433.70%) (33.94%) (50.12%)
Return on assets (44.77%) (27.20%) (45.60%)
Return on invested capital 0.00% (80.00%) 0.00%

Growth

Metric CELC DNLI Biotechnology median
Revenue growth (TTM) — (93.40%) 6.26%
EPS growth (last fiscal year) (33.92%) (15.56%) 29.88%
Revenue growth, 5-year CAGR — 20.67% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CELC DNLI Biotechnology median
Debt to equity (58.93) 0.01 0.00
Current ratio 8.93 6.21 4.89
Net debt to EBITDA 0.71 1.56 1.01

Dividend

Metric CELC DNLI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CELC DNLI Biotechnology median
Market cap 3.13b 3.16b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack